CAMP4 Therapeutics Corporation (CAMP) |
| 4.52 -0.12 (-2.59%) 04-14 16:00 |
| Open: | 4.84 |
| High: | 5.08 |
| Low: | 4.46 |
| Volume: | 82,239 |
| Market Cap: | 96(M) |
| PE Ratio: | -1.71 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 6.65 |
| Resistance 1: | 5.60 |
| Pivot price: | 4.49 |
| Support 1: | 3.89 |
| Support 2: | 3.24 |
| 52w High: | 7.75 |
| 52w Low: | 1.305 |
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Financials
| EPS | -50420000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -3.00 |
| Return on Assets (ttm) | 671.3 |
| Return on Equity (ttm) | -33.2 |
Company news
Tue, 14 Apr 2026
CAMP Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Tue, 14 Apr 2026
Rodman & Renshaw Initiates Camp4 Therapeutics(CAMP.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
Tue, 14 Apr 2026
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com India
Tue, 14 Apr 2026
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
Mon, 13 Apr 2026
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - Yahoo Finance
Wed, 08 Apr 2026
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
